Imfinzi

Active substance durvalumab
Holder AstraZeneca AB
Status closed
Indication First-line Treatment for Patients with Locally Advanced or Metastatic Biliary Tract Cancers in combination with Gemcitabine Plus Cisplatin Therapies
Public documents Approbation
  Information for the patient
  Informed consent
Last update 03/02/2023

 

Last updated on 13/02/2024